Biomedical Research Institute Of Southern California
- Assets
- $60.3k
- Revenue
- $208.2k
- Investments
- $0.0
- Employees
- 3
- Location
- Oceanside, CA
- Founding
- 03/2012
- Data as of
- 12/2023
- EIN
- 45-2210161
Organization Overview
Biomedical Research Institute Of Southern California is located in Oceanside, CA. The organization was established in 2012. According to its NTEE Classification (H92) the organization is classified as: Biomedicine & Bioengineering Research, under the broad grouping of Medical Research and related organizations. As of 12/2023, Biomedical Research Institute Of Southern California employed 3 individuals. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Biomedical Research Institute Of Southern California is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 12/2023, Biomedical Research Institute Of Southern California generated $208.2k in total revenue. This represents a relatively dramatic decline in revenue. Over the past 9 years, the organization has seen revenues fall by an average of (16.7%) each year. All expenses for the organization totaled $189.0k during the year ending 12/2023. As we would expect to see with falling revenues, expenses have declined by (17.6%) per year over the past 9 years. You can explore the organizations financials more deeply in the financial statements section below.
Form
990
Mission & Program ActivityExcerpts From the 990 Filing
TAX YEAR
2023
Describe the Organization's Mission:
Part 3 - Line 1
TO CONDUCT BASIC AND TRANSLATIONAL BIOMEDICAL RESEARCH AIMED AT UNDERSTANDING, PREVENTING OR CURING HUMAN DISEASE.
Describe the Organization's Program Activity:
Part 3 - Line 4a
VIRAL IMMUNOLOGYTHE OBJECTIVE OF THIS PROGRAM IS TO CONDUCT RESEARCH INTO THE MECHANISMS BY WHICH THE IMMUNE SYSTEM PROTECTS AGAINST VIRAL INFECTIONS. THIS RESEARCH WILL HELP US TO DEVELOP BETTER VACCINES AND THERAPEUTIC AGENTS FOR VIRAL INFECTIONS. THIS PROGRAM INCLUDES PRE-CLINICAL WORK ON A NOVEL UNIVERSAL INFLUENZA VACCINE, THE MECHANISM BY WHICH IT PROTECTS AGAINST MULTIPLE STRAINS OF INFLUENZA AND WHETHER THE VACCINE PROTECTS AGAINST SECONDARY BACTERIAL INFECTIONS OFTEN INCREASE MORTALITY FROM INFLUENZA. WE ARE ALSO INVESTIGATING NOVEL VACCINE ADJUVANTS AND WHY IMMUNE RESPONSES TO CERTAIN VACCINES WANE OVER TIME.
DIABETESTHE GOAL OF THIS PROGRAM IS TO IDENTIFY UNIQUE EVENTS AND MOLECULAR PATHWAYS THAT CAN TRIGGER THE AUTOREACTIVE T CELLS TO CAUSE DESTRUCTION OF THE PANCREATIC ISLETS IN TYPE 1 DIABETES. THE ROLE OF EXOSOMES AND NOVEL SELF-ANTIGENS ENCODED BY ENDOGENOUS RETROVIRUSES IS A MAJOR FOCUS OF THIS STUDY.
THE BLOOD BRAIN BARRIERTHE BLOOD-BRAIN BARRIER (BBB) PREVENTS BLOODBORNE SUBSTANCES FROM NON-SELECTIVELY CROSSING INTO THE BRAIN AND PLAYS A CRUCIAL ROLE IN PROTECTING THE BRAIN FROM HARMFUL SUBSTANCES AND PATHOGENS. HOWEVER, THE BBB ALSO SIGNIFICANTLY IMPEDES THE DELIVERY OF THERAPEUTIC AGENTS INTO THE BRAIN WHICH PRESENTS A MAJOR CHALLENGE FOR THE TARGETING AND DELIVERY OF PHARMACOLOGICAL AGENTS FOR THE TREATMENT OF VARIOUS CENTRAL NERVOUS SYSTEM (CNS) DISEASES, INCLUDING CANCERS, HIV INFECTION AND ALZHEIMER'S DISEASE. BRISC SCIENTISTS ARE STUDYING THE ROLE OF THE BBB IN HEALTH AND DISEASE AND ARE CONDUCTING COLLABORATIVE STUDIES ON NOVEL METHODS OF REVERSIBLY PERMEABILIZING THE BBB TO ALLOW ENTRY OF THERAPEUTIC AGENTS.
Get More from Intellispect for FreeCreate a free account to get more data, nonprofit salaries, advanced search and more.
Board, Officers & Key Employees
| Name (title) | Role | Hours | Compensation |
|---|---|---|---|
Dr Craig Jackson Chairman Of Board Of Direc | Trustee | 0.5 | $0 |
Dr Leman Yel Director | Trustee | 0.3 | $0 |
Dr Peter Dias CFO | OfficerTrustee | 20 | $0 |
Mr Michael Giske Director | Trustee | 0.5 | $0 |
Dr Sally Sarawar President And CEO | Officer | 20 | $34,683 |
Financial Statements
| Statement of Revenue | |
|---|---|
| Federated campaigns | $0 |
| Membership dues | $0 |
| Fundraising events | $0 |
| Related organizations | $0 |
| Government grants | $0 |
| All other contributions, gifts, grants, and similar amounts not included above | $178,181 |
| Noncash contributions included in lines 1a–1f | $0 |
| Total Revenue from Contributions, Gifts, Grants & Similar | $178,181 |
| Total Program Service Revenue | $0 |
| Investment income | $0 |
| Tax Exempt Bond Proceeds | $0 |
| Royalties | $0 |
| Net Rental Income | $30,068 |
| Net Gain/Loss on Asset Sales | $0 |
| Net Income from Fundraising Events | $0 |
| Net Income from Gaming Activities | $0 |
| Net Income from Sales of Inventory | $0 |
| Miscellaneous Revenue | $0 |
| Total Revenue | $208,249 |
| Statement of Expenses | |
|---|---|
| Grants and other assistance to domestic organizations and domestic governments. | $0 |
| Grants and other assistance to domestic individuals. | $0 |
| Grants and other assistance to Foreign Orgs/Individuals | $0 |
| Benefits paid to or for members | $0 |
| Compensation of current officers, directors, key employees. | $7,272 |
| Compensation of current officers, directors, key employees. | $7,272 |
| Compensation to disqualified persons | $0 |
| Other salaries and wages | $86,767 |
| Pension plan accruals and contributions | $0 |
| Other employee benefits | $7,079 |
| Payroll taxes | $0 |
| Fees for services: Management | $0 |
| Fees for services: Legal | $0 |
| Fees for services: Accounting | $1,450 |
| Fees for services: Lobbying | $0 |
| Fees for services: Fundraising | $0 |
| Fees for services: Investment Management | $0 |
| Fees for services: Other | $2,526 |
| Advertising and promotion | $0 |
| Office expenses | $1,235 |
| Information technology | $0 |
| Royalties | $0 |
| Occupancy | $8,454 |
| Travel | $335 |
| Payments of travel or entertainment expenses for any federal, state, or local public officials | $0 |
| Conferences, conventions, and meetings | $0 |
| Interest | $0 |
| Payments to affiliates | $0 |
| Depreciation, depletion, and amortization | $0 |
| Insurance | $2,990 |
| All other expenses | $0 |
| Total functional expenses | $188,995 |
| Balance Sheet | |
|---|---|
| Cash—non-interest-bearing | $60,381 |
| Savings and temporary cash investments | $0 |
| Pledges and grants receivable | $0 |
| Accounts receivable, net | -$51 |
| Loans from Officers, Directors, or Controlling Persons | $0 |
| Loans from Disqualified Persons | $0 |
| Notes and loans receivable | $0 |
| Inventories for sale or use | $0 |
| Prepaid expenses and deferred charges | $0 |
| Net Land, buildings, and equipment | $0 |
| Investments—publicly traded securities | $0 |
| Investments—other securities | $0 |
| Investments—program-related | $0 |
| Intangible assets | $0 |
| Other assets | $0 |
| Total assets | $60,330 |
| Accounts payable and accrued expenses | $7,528 |
| Grants payable | $0 |
| Deferred revenue | $485 |
| Tax-exempt bond liabilities | $0 |
| Escrow or custodial account liability | $0 |
| Loans and other payables to any current Officer, Director, or Controlling Person | $30,000 |
| Secured mortgages and notes payable | $0 |
| Unsecured mortgages and notes payable | $0 |
| Other liabilities | $17,463 |
| Total liabilities | $55,476 |
| Net assets without donor restrictions | $4,854 |
| Net assets with donor restrictions | $0 |
| Capital stock or trust principal, or current funds | $0 |
| Paid-in or capital surplus, or land, building, or equipment fund | $0 |
| Retained earnings, endowment, accumulated income, or other funds | $0 |
| Total liabilities and net assets/fund balances | $60,330 |